DoseFinding

CRM Simulation Checklist

During 2019, I was working on simulations using CRM designs in several different trials. I found I would frequently get the designs mixed up: “We are targeting 20% toxicity in this trial, right? No, that was the other trial…we are targeting 33% here…” Similarly, once or twice, I got to the stage where I wanted to run simulations only to discover we had not specified some important design aspect, like when the trial should stop.

How to design a dose-finding study using the continual reassessment method

The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in targeting the MTD than traditional rule-based approaches such as the 3 + 3 design, which is used in most phase I trials.

Combination Lenalidomide and Azacitidine - A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and azacitidine (AZA) possess significant antitumor activity effect in AML.

Implementing the EffTox dose-finding design in the Matchpoint trial

The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience implementing EffTox in the Matchpoint trial.